Back to top
more

Aptinyx Inc. (APTX)

(Delayed Data from NSDQ)

$3.78 USD

3.78
313,385

+0.03 (0.80%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.79 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

by Zacks Equity Research

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.

McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.

Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.

Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss

by Zacks Equity Research

Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.

Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

by Zacks Equity Research

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

by Zacks Equity Research

Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

by Zacks Equity Research

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

by Zacks Equity Research

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.

Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck

by Zacks Equity Research

Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.

Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails

by Zacks Equity Research

Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

by Zacks Equity Research

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.

Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study

by Zacks Equity Research

Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.

Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail

by Zacks Equity Research

Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.

Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio

by Zacks Equity Research

Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.

Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug

by Zacks Equity Research

Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.

Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update

by Zacks Equity Research

Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.

Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod

by Zacks Equity Research

The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.

Apellis (APLS) Kindles Acquisition Interest Per Bloomberg

by Zacks Equity Research

Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.

Avidity (RNA) Down on Update From Neuromuscular Disease Study

by Zacks Equity Research

Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.

Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.